Publications

Jeronimo Martinez Garcia publications

49 results

2026

  1. Corrigendum to “Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery” [Gynecol Oncol. 2026 Apr;207:16-22. doi:10.1016/j.ygyno.2026.02.014. Epub 2026 Feb 25. PMID: 41747472] (Gynecologic Oncology (2026) 207 (16–22), (S0090825826008085), (10.1016/j.ygyno.2026.02.014))

    Gynecologic Oncology

  2. Neoadjuvant Chemotherapy Following Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Retrospective Cohort Study

    Cancers, Vol. 18, Núm. 5

  3. Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer

    British Journal of Cancer, Vol. 134, Núm. 12, pp. 1754-1763

  4. Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery

    Gynecologic Oncology, Vol. 207, pp. 16-22

  5. The myth of eradicating peritoneal surface malignancies: How ultramicroscopic disease undermines the potential benefits of hyperthermic intraperitoneal chemotherapy

    European Journal of Surgical Oncology, Vol. 52, Núm. 10

  6. Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer

    Breast Cancer Research and Treatment, Vol. 215, Núm. 2

2025

  1. Challenges of Nontherapeutic Laparotomy in Patients with Peritoneal Surface Malignancies Selected for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

    Cancers, Vol. 17, Núm. 9

  2. Combined Hyperthermic Intraperitoneal Chemotherapy and Normothermic Intraperitoneal Chemotherapy Long-Term After Interval Cytoreduction in Ovarian Cancer: A Phase I Clinical Trial (BICOV1)

    Cancers, Vol. 17, Núm. 12

  3. Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation

    The oncologist, Vol. 30, Núm. 5

  4. Peritoneal cancer index in ovarian cancer: what does the surgeon really see?

    Clinical and Translational Oncology, Vol. 27, Núm. 11, pp. 4185-4191

  5. SEOM-GEIS Spanish clinical guidelines for the management of soft‑tissue sarcomas (2024)

    Clinical and Translational Oncology, Vol. 27, Núm. 4, pp. 1460-1471

  6. Tratamientos

    Diseño de programas de ejercicio físico en población oncológica (Síntesis), pp. 63-125

  7. VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol

    Pharmaceuticals, Vol. 18, Núm. 12

  8. [Translated article] Real-World Evidence of Adjuvant Immunotherapy in Resected Stage III and IV Melanoma Patients: CADIM Trial Final Results. Experience From 2 Tertiary Referral Centers

    Actas Dermo-Sifiliograficas

2024

  1. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 403, Núm. 10421, pp. 31-43

  2. Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcoma

    Therapeutic Advances in Medical Oncology, Vol. 16

  3. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

    Gynecologic Oncology, Vol. 185, pp. 202-211

  4. Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol

    Pharmaceutics, Vol. 16, Núm. 12

  5. Real-World Evidence of Adjuvant Immunotherapy in Resected Stage III and IV Melanoma Patients: CADIM Trial Final Results. Experience from 2 Tertiary Referral Centers

    Actas Dermo-Sifiliograficas

  6. Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study

    BMC Cancer, Vol. 24, Núm. 1